Dr. Yentz on Navigating Frontline Treatment Selection in RCC


In Partnership With:

Sarah Elizabeth Yentz, MD, discusses navigating frontline treatment selection in renal cell carcinoma.

Sarah Elizabeth Yentz, MD, clinical assistant professor, University of Michigan Health, medical oncologist, Brighton Center for Specialty Care, Rogel Cancer Center, Michigan Medicine, discusses navigating frontline treatment selection in renal cell carcinoma (RCC).

It can be difficult to select between available frontline regimens for patients with RCC. Moreover, patients are often eligible for several regimens, which further complicates treatment selection, Yentz explains.

For young patients with a low volume of disease, ipilimumab (Yervoy) in combination with nivolumab (Opdivo) is preferred because it can elicit durable complete responses, Yentz says. The combination regimens of immunotherapy and TKIs are preferred for patients with symptomatic, rapidly progressing disease because the rate of primary progression is lower with these doublets vs with ipilimumab/nivolumab.

Notably, many patients are candidates for ipilimumab/nivolumab and immunotherapy/TKI regimens, so treatment selection should be based on other factors, such as patient comorbidities and disease characteristics, in these situations, Yentz concludes.

Related Videos
Jeffrey Zonder, MD
Jun Gong, MD
John Michael Bryant, MD,
Chandler H. Park, MD, FACP
Kathryn Beckermann, MD, PhD
Eleonora Dondossola, PhD
William B. Pearse, MD
Pasi A. Jänne, MD, PhD, director, Lowe Center for Thoracic Oncology, director, Belfer Center for Applied Cancer Science, director, Chen-Huang Center for EGFR Mutant Lung Cancers, senior physician, David M. Livingston, MD, Chair, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Rachid Baz, MD, section head, Myeloma, Department of Malignant Hematology, Moffitt Cancer Center; co-director, Pentecost Family Myeloma Research Center
Harriet Kluger, MD, Harvey and Kate Cushing Professor of Medicine (Oncology) and of Dermatology; director, Yale SPORE in Skin Cancer; vice chair, Translational Research, Internal Medicine; chief, Division of Skin and Kidney Cancer; associate cancer center director, Education, Training and Faculty Development; deputy section chief, Medical Oncology, Yale Cancer Center